ESTA
BEARISH
$62.01
Live
Establishment Labs Holdings Inc. · NASDAQ
Target $88.0
(+41.9%)
$28.67
52W Range
$83.31
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$1.82B
P/E
N/A
ROE
-133.3%
Profit margin
-24.2%
Debt/Equity
11.23
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
ESTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Key Strengths
Strong revenue growth of 45.2%
Key Risks
Low profit margin of -24.2%
Weak financial trend (Piotroski F-Score: 3/9)
High debt burden with D/E of 11.23
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
33
Weak
50
65
30
20
0
AI Verdict
ESTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Key drivers: Strong revenue growth of 45.2%, Low profit margin of -24.2%, Weak financial trend (Piotroski F-Score: 3/9)
Confidence
25%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 45.2%.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -10.1% over 5Y and +127.1% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -133.3%.
- Thin profit margins.
Health
20/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
- High D/E ratio (11.23).
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$62.01
Analyst Target
$88.0
Upside/Downside
+41.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ESTA and closest competitors.
Updated 2026-04-08
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ESTA
Establishment Labs Holdings Inc.
Primary
|
-10.1% | -12.1% | +127.1% | +54.6% | -10.2% | +5.6% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
EST
Establishment Labs Holdings Inc.
Primary
5Y
-10.1%
3Y
-12.1%
1Y
+127.1%
6M
+54.6%
1M
-10.2%
1W
+5.6%
AZT
Azenta, Inc.
Peer
5Y
-50.6%
3Y
-29.6%
1Y
-26.9%
6M
+16.3%
1M
+16.1%
1W
+0.1%
ANA
AnaptysBio, Inc.
Peer
5Y
+227.2%
3Y
+183.1%
1Y
+284.9%
6M
+177.0%
1M
+17.3%
1W
+17.0%
ADU
Addus HomeCare Corporation
Peer
5Y
-6.0%
3Y
+1.0%
1Y
+11.6%
6M
-8.1%
1M
-10.1%
1W
-1.8%
AUP
Aurinia Pharmaceuticals Inc.
Peer
5Y
-22.4%
3Y
+77.0%
1Y
+81.0%
6M
+62.7%
1M
-10.7%
1W
-2.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
302.49
PEG Ratio
N/A
P/B Ratio
77.13
P/S Ratio
8.61
EV/Revenue
9.51
EV/EBITDA
-68.16
Market Cap
$1.82B
Profitability
Profit margins and return metrics
Profit Margin
-24.19%
Operating Margin
-6.08%
Gross Margin
69.31%
ROE
-133.25%
ROA
-6.93%
Growth
Revenue and earnings growth rates
Revenue Growth
+45.2%
Earnings Growth
N/A
Q/Q Revenue Growth
+45.16%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
11.23
High debt
Current Ratio
3.04
Strong
Quick Ratio
1.86
Excellent
Cash/Share
$2.58
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
70.5%
Op. Margin
-6.1%
Net Margin
-4.0%
Total Assets
$0.4B
Liabilities
$0.3B
Equity
$0.0B
Debt/Equity
14.17x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
1125%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-24
$-0.09
+58.1% surprise
2025-11-05
$-0.38
+26.0% surprise
2025-08-07
$-0.56
+1.8% surprise
Healthcare Sector Comparison
Comparing ESTA against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
Return on Equity (ROE)
-133.25%
This Stock
vs
-44.08%
Sector Avg
+202.3%
(Excellent)
Profit Margin
-24.19%
This Stock
vs
-19.57%
Sector Avg
+23.6%
(Superior)
Debt to Equity
11.23
This Stock
vs
5.1
Sector Avg
+120.4%
(Higher)
Revenue Growth
45.2%
This Stock
vs
108.17%
Sector Avg
-58.2%
(Slower)
Current Ratio
3.04
This Stock
vs
3.39
Sector Avg
-10.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ESTA
Establishment Labs Holdings Inc.
|
BEARISH | $1.82B | - | -133.3% | -24.2% | $62.01 | |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | Compare |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | Compare |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | Compare |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 | Compare |
ESTA
Establishment...
BEARISH
Mkt Cap
$1.8B
P/E
-
ROE
-133.3%
Price
$62.01
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | SCHUTTER EDWARD JAMES | Director | Option Exercise | 36,780 | $151,166 |
| 2026-03-31 | SCHUTTER EDWARD JAMES | Director | Stock Award | 330 | $18,737 |
| 2026-03-31 | LEWIN NICHOLAS SHERIDAN | Director | Stock Award | 440 | $24,983 |
| 2026-03-31 | CUSTIN ANN | Director | Stock Award | 363 | $20,611 |
| 2026-03-31 | SLOTKIN BRYAN | Director | Stock Award | 286 | $16,239 |
| 2026-03-31 | GILLIN LESLIE | Director | Stock Award | 297 | $16,864 |
| 2026-03-25 | CHACON QUIROS JUAN JOSE | Director | Sale | 3,575 | $214,768 |
| 2026-03-23 | CHACON QUIROS JUAN JOSE | Director | Sale | 33,925 | $2,048,697 |
| 2026-03-09 | HARRIS CASSANDRA | Chief Financial Officer | Stock Award | 7,372 | - |
| 2026-02-18 | CALDINI FILIPPO | Chief Executive Officer | Stock Award | 8,185 | - |
| 2026-02-13 | MANSBACH SAMUEL ROSS | General Counsel | Stock Award | 4,082 | - |
| 2025-12-31 | SCHUTTER EDWARD JAMES | Director | Stock Award | 257 | $18,730 |
| 2025-12-31 | LEWIN NICHOLAS SHERIDAN | Director | Stock Award | 343 | $24,998 |
| 2025-12-31 | CUSTIN ANN | Director | Stock Award | 282 | $20,552 |
| 2025-12-31 | SLOTKIN BRYAN | Director | Stock Award | 222 | $16,179 |
SCHUTTER EDWARD JAMES
Director
2026-04-02
36,780 shares
·
$151,166
SCHUTTER EDWARD JAMES
Director
2026-03-31
330 shares
·
$18,737
LEWIN NICHOLAS SHERIDAN
Director
2026-03-31
440 shares
·
$24,983
CUSTIN ANN
Director
2026-03-31
363 shares
·
$20,611
SLOTKIN BRYAN
Director
2026-03-31
286 shares
·
$16,239
GILLIN LESLIE
Director
2026-03-31
297 shares
·
$16,864
CHACON QUIROS JUAN JOSE
Director
2026-03-25
3,575 shares
·
$214,768
CHACON QUIROS JUAN JOSE
Director
2026-03-23
33,925 shares
·
$2,048,697
HARRIS CASSANDRA
Chief Financial Officer
2026-03-09
7,372 shares
CALDINI FILIPPO
Chief Executive Officer
2026-02-18
8,185 shares
MANSBACH SAMUEL ROSS
General Counsel
2026-02-13
4,082 shares
SCHUTTER EDWARD JAMES
Director
2025-12-31
257 shares
·
$18,730
LEWIN NICHOLAS SHERIDAN
Director
2025-12-31
343 shares
·
$24,998
CUSTIN ANN
Director
2025-12-31
282 shares
·
$20,552
SLOTKIN BRYAN
Director
2025-12-31
222 shares
·
$16,179
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
Citigroup
2026-03-11
Neutral
Neutral
Canaccord Genuity
2026-02-26
Buy
Buy
Stephens & Co.
2026-02-25
Overweight
Overweight
Mizuho
2026-02-25
Outperform
Outperform
Needham
2026-02-24
Buy
Buy
BTIG
2026-02-24
Buy
Buy
Needham
2026-01-12
Buy
Buy
BTIG
2025-12-31
Buy
Buy
Canaccord Genuity
2025-12-17
Buy
Buy
JP Morgan
2025-12-17
Overweight
Overweight
Past News Coverage
Recent headlines mentioning ESTA from our newsroom.
Newest → oldest
No matching news yet.